| Sigma S, a measure of reactive sulfur groups of immunoglobulin G, is a sensitive tumor marker discriminating different stages of breast cancer. | |
| | |
MedLine Citation:
|
PMID: 1913474 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sigma S is a measure of the disulfide bonds and free thiol groups of serum immunoglobulin (Ig) G, as determined by the reaction with dithionitrobenzoate. Significant decreases of sigma S previously were detected in malignant compared with benign diseases of various organs. This study shows the application of sigma S for the diagnosis of breast cancer. The following results were obtained. First, 132 patients with benign breast diseases showed a sigma S of 1.48 +/- 0.29 (standard deviation) per mole IgG; this was not different from 1.51 +/- 0.36 found in 182 controls. In contrast, IgG from 198 patients with primary breast carcinoma of all four stages (tumor-node-metastasis system) gave a sigma S of 1.22 +/- 0.29, a significant (P less than 0.0001) decrease of sigma S from benign to malignant breast disease. Second, sigma S values of single Stages I, II, III, and IV, were 1.27 (n = 59), 1.23 (n = 83), 1.19 (n = 35), and 1.10 (n = 21), respectively, each significantly different from sigma S in benign disease and showing a decreasing trend with increasing tumor progress. Differences were significant between Stages I and IV (P less than 0.025) and II and IV (P less than 0.05). Third, 63% of Stage I breast carcinoma patients had sigma S values below a critical threshold of 1.38. This serum positivity rose to 90% in Stage IV. These values exceeded those reported with other tumor markers. The overall power of sigma S to distinguish between benign and malignant breast disease had a specificity of 61% and a sensitivity of 78%. Early stages (I and II) of breast cancer could be distinguished from benign diseases with 64% specificity and 69% sensitivity. Advanced Stage IV could be discriminated from early Stages I and II with 55% specificity and 71% sensitivity. Thus, the analysis of sigma S may significantly contribute to the surveillance of patients with breast cancer. |
| | |
Authors:
|
M G Smola; W Estelberger; M Reiter; K Schauenstein; E Schauenstein |
Related Documents
:
|
9329574 - Value of cyfra 21-1, tpa, and scc-ag in predicting extracervical disease and prognosis ... 20215424 - Next generation sequencing of serum circulating nucleic acids from patients with invasi... 48004 - Correlation of the blood-level of a pregnancy-associated alpha-macroglobulin with the c... 9291824 - Serum m3/m21 in cervical cancer patients. 10630364 - Expanding options in breast cancer. 22077934 - Cost-effectiveness of prostate health index for prostate cancer detection. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 68 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 1991 Sep |
Date Detail:
|
Created Date: 1991-11-12 Completed Date: 1991-11-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1026-30 Citation Subset: AIM; IM |
Affiliation:
|
Department of Surgery, School of Medicine, University of Graz, Austria. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analysis of Variance Breast Neoplasms / blood*, pathology Disulfides / analysis, blood Female Humans Immunoglobulin G / analysis, chemistry* Middle Aged Neoplasm Staging / methods* Sulfhydryl Compounds / analysis, blood Tumor Markers, Biological / analysis*, blood |
| Chemical | |
Reg. No./Substance:
|
0/Disulfides; 0/Immunoglobulin G; 0/Sulfhydryl Compounds; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of sympt...
Next Document: Malignant histiocytosis X. A distinct clinicopathologic entity.